Wolfe starts J&J at Outperform, sees growth drivers as ‘best-in-class’
Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target ...
verywellhealth6h
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Outsourcing-pharma14h
Tirzepatide prevents type 2 diabetes in 99% of prediabetic patients for 3 years
Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...
2 Top Growth Stocks to Buy on the Dip
Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...
clinicaltrialsarena17h
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...
Benefits Pro21h
Obesity drug cost crisis will end, Swiss Re analysts say
The current pain caused by the high cost of the GLP-1 agonist anti-obesity drugs will pass. Prachi Patkee and other analysts ...